# A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Study · id `cardio:ct-nct02992288` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02992288](<https://clinicaltrials.gov/study/NCT02992288>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02992288

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 427 participants.

## Technical summary

Registry record NCT02992288. Randomized; quadruple masking; primary purpose treatment. Start 2017-02-22 (actual); primary completion 2018-03-28 (actual). Results posted on 2019-04-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 427 participants (enrolled count; ClinicalTrials.gov record NCT02992288, source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)
- Started: 2017-02-22 (actual) (ClinicalTrials.gov record NCT02992288, source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)
- Primary completion: 2018-03-28 (actual) (ClinicalTrials.gov record NCT02992288, source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)
- Completion: 2018-05-16 (actual) (ClinicalTrials.gov record NCT02992288, source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)
- Results first posted: 2019-04-23 (ClinicalTrials.gov record NCT02992288, source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)
- Countries: United States; Belgium; Bulgaria; Germany; Greece; Israel; Italy; Japan; Netherlands; Poland; Spain (ClinicalTrials.gov record NCT02992288, source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02992288-2019-04-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
- Acronym: PANTHEON
- Condition: Heart Failure
- Intervention (Drug): Neladenoson bialanate (BAY1067197)
- Intervention (Drug): Neladenoson bialanate (BAY1067197)
- Intervention (Drug): Neladenoson bialanate (BAY1067197)
- Intervention (Drug): Neladenoson bialanate (BAY1067197)
- Intervention (Drug): Neladenoson bialanate (BAY1067197)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial (`cardio:pubmed-31523892`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1dda11d5a824d543bd197b21d3372f46950b81670db2c0a9c349905a17dda90c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
